Immix Biopharma (IMMX) Q2 2025 earnings summary

Executive summary

• Focused on CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, with ongoing Phase 1b/2 trials in the US and ex-US, and expansion to 18 clinical sites as of July 2025.

• NXC-201 has received FDA RMAT and Orphan Drug Designation, as well as European ODD, and has shown high response rates in clinical data presented at major conferences.

• Awarded an $8M CIRM grant to support NXC-201 clinical development, with $3.6M received and $4.4M remaining as of August 2025.

• Company operates as a single segment, with all significant decisions made at the consolidated level.

Financial highlights

• Cash and cash equivalents were $11.6M as of June 30, 2025, with $12M reported in a subsequent update.

• Net loss for Q2 2025 was $6.6M, up from $4.4M in Q2 2024; net loss for the six months ended June 30, 2025 was $11.2M, up from $9.7M year-over-year.

• General and administrative expenses for Q2 2025 were $2.7M (up from $2.5M), and R&D expenses were $4.0M (up from $2.2M) compared to Q2 2024.

• Interest income declined to $104K in Q2 2025 from $307K in Q2 2024 due to lower cash balances.

• Net cash used in operating activities for the six months ended June 30, 2025 was $7.0M, down from $9.1M in the prior year period.

Outlook and guidance

• Management expects continued operating losses and insufficient capital to fund operations for the next twelve months, indicating substantial doubt about the ability to continue as a going concern.

• Plans to seek additional capital through equity, debt, grants, or strategic partnerships; alternatives to the current business plan may be considered if funding is not secured.